Last week, the FDA's intensified cybersecurity enforcement sent shockwaves through the MedTech industry, leading to a surge in 'Refuse to Accept' notices for new device submissions. This episode of MedTech Global Insights delves into the critical new requirements that are halting market access and catching even seasoned companies off guard.

We uncover why traditional regulatory strategies are no longer sufficient and how the FDA's mandate for a total product lifecycle security plan is fundamentally reshaping MedTech innovation. Learn about the specific documentation, like the Software Bill of Materials (SBOM), that has become a make-or-break component of any successful US submission.

**Case Study:** A promising European AI diagnostics company, fresh off their EU approval, was blocked from the US market. Their critical error? A submission lacking a detailed SBOM, an oversight that triggered a costly six-month delay and jeopardized their next funding round.

**Key Takeaways:**

- Why is the FDA suddenly rejecting so many submissions on cybersecurity grounds?

- What is a Software Bill of Materials (SBOM) and why is it now non-negotiable?

- How does the "Secure Product Development Framework" change your R&D process?

- What are the three most common cybersecurity mistakes in a 510(k) submission?

- Is your post-market surveillance plan robust enough for zero-day vulnerabilities?

- How can you leverage your EU MDR technical file for the new FDA requirements?

- What is the real cost of a "Refuse to Accept" notice beyond the regulatory fees?

For more information, contact us at [email protected] or visit https://pureglobal.com/. For FREE AI tools and a free medical device database, visit https://pureglobal.ai/.